The Effect of Biosimilars [Inflectra®] in the Management of Acute Severe Ulcerative Colitis

J Crohns Colitis. 2017 Oct 27;11(11):1400-1401. doi: 10.1093/ecco-jcc/jjx059.

Authors

Grace Harkin¹, Áine Keogh¹, Eoin Slattery¹

Affiliation

¹ Department of Gastroenterology, University Hospital Galway, Galway, Ireland.

PMID: 28444254
DOI: 10.1093/ecco-jcc/jjx059

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Acute Disease
Adalimumab / administration & dosage*
Adult
Biosimilar Pharmaceuticals / administration & dosage
Biosimilar Pharmaceuticals / adverse effects
Colitis, Ulcerative* / diagnosis
Colitis, Ulcerative* / drug therapy
Colitis, Ulcerative* / physiopathology
Drug Monitoring
Drug Substitution / methods
Female
Gastrointestinal Agents / administration & dosage
Gastrointestinal Agents / adverse effects
Humans
Infliximab* / administration & dosage
Infliximab* / adverse effects
Ireland
Male
Severity of Illness Index
Treatment Outcome

Substances

Biosimilar Pharmaceuticals
Gastrointestinal Agents
Infliximab
Adalimumab